At the time of writing, Capricor Therapeutics Inc [CAPR] stock is trading at $11.15, up 9.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CAPR shares have gain 6.39% over the last week, with a monthly amount drifted -5.99%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Capricor Therapeutics Inc [NASDAQ: CAPR] stock has seen the most recent analyst activity on May 20, 2025, when Roth Capital initiated its Buy rating and assigned the stock a price target of $31. Previously, Piper Sandler started tracking the stock with Overweight rating on October 21, 2024, and set its price target to $35. On May 17, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $14 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $8 on January 05, 2024. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $15 as its price target on October 26, 2022. Maxim Group downgraded its rating to Hold for this stock on December 26, 2018. In a note dated January 26, 2018, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $6.50 to $8.60.
For the past year, the stock price of Capricor Therapeutics Inc fluctuated between $3.52 and $23.40. Currently, Wall Street analysts expect the stock to reach $15.38 within the next 12 months. Capricor Therapeutics Inc [NASDAQ: CAPR] shares were valued at $11.15 at the most recent close of the market. An investor can expect a potential return of 37.94% based on the average CAPR price forecast.
Analyzing the CAPR fundamentals
According to Capricor Therapeutics Inc [NASDAQ:CAPR], the company’s sales were 17.36M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -3.3%, Pretax Profit Margin comes in at -3.17%, and Net Profit Margin reading is -3.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.62 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.94 points at the first support level, and at 8.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.94, and for the 2nd resistance point, it is at 12.73.
Ratios To Look Out For
It is important to note that Capricor Therapeutics Inc [NASDAQ:CAPR] has a current ratio of 6.55. As well, the Quick Ratio is 6.55, while the Cash Ratio is 1.29. Considering the valuation of this stock, the price to sales ratio is 29.36, the price to book ratio is 3.99.
Transactions by insiders
Recent insider trading involved Nippon Shinyaku Co Ltd, 10% Owner, that happened on Sep 20 ’24 when 2.8 million shares were purchased.
